CNS-penetrant
Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
Rakovina Therapeutics; AI-discovered drugs; CNS-penetrant; ATR/mTOR inhibitors; preclinical data; Society for Neuro-Oncology; brain cancer; PTEN-deficient tumors; Enki generative AI; dual pathway inhibition